LP-935509

• Description:

  LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM) . LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research[1].

• Product Name Alternative:

  6-Hydroxybentazone

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  AAK1; Cyclin G-associated Kinase (GAK) ; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/lp-935509.html

• Purity:

  99.74

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C (N1CCN (C2=NC3=C (C4=CC=CN=C4OC) C=NN3C=C2) CC1) OC (C) C

• Molecular Formula:

  C20H24N6O3

• Molecular Weight:

  396.44

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Kostich W, et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358 (3) :371-86.|[2]Mushtaq, et al. Role Of Endocytic Machinery Regulators in EGFR Traffic and Viral Entry (2021) . Theses & Dissertations. 532.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1454555-29-3